A study with the aim of evaluating the prophylactic efficacy of the human pappilomavirus (HPV) quadrivalent vaccine in preventing low grade cervical, vulvar, and vaginal intraepithelial neoplasias and anogenital warts wwas sponsored by Research Laboratories, a division of Merck and Company, maker of the vaccine Gardasil.
It was concluded that the vaccine Gardasil did provide a sustained protection against low grade lesions attributable to HPV types 6,11,16 and 18. There was also a substantial reduction in the burden of diseases through 42 months of follow-up.
*Disclaimer: Tinglan2013 does not endorse that said product. We merely want to share information we found over the net.